Cite
HARVARD Citation
Élez, E. et al. (n.d.). Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Annals of oncology. pp. 132-140. [Online].